BioMimetic Therapeutics, Inc. to Report Third Quarter 2012 Financial Results on November 5
2012年11月2日 - 12:00AM
ビジネスワイヤ(英語)
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced
that the Company plans to release its financial results for the
three and nine months ended September 30, 2012, on Monday, November
5 after the close of market. The Company will host a conference
call and audio webcast to discuss its third quarter financial
results, product development programs and business activities at
4:30 p.m. EST the same day.
The conference call may be accessed on November 5, 2012, by
dialing (877) 224 - 4059 for U.S. and Canadian callers (passcode:
56458053). The international dial in number is (706) 902 - 2069,
and the same passcode applies. Participants should dial in 10
minutes prior to the call.
A live webcast of the conference call will be available on the
Investor Relations section of BioMimetic’s website at
www.biomimetics.com. The webcast will be archived for at least 30
days following the call.
About BioMimetic Therapeutics
BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology
company specializing in the development and commercialization of
clinically proven products to promote the healing of
musculoskeletal injuries and diseases, including therapies for
orthopedics, sports medicine and spine applications. All Augment®
branded products are based upon recombinant human platelet-derived
growth factor (rhPDGF-BB), which is an engineered form of PDGF, one
of the body’s principal agents to stimulate and direct healing and
regeneration. Through the commercialization of this patented
technology, BioMimetic seeks to become the leading company in the
field of regenerative medicine by providing new treatment options
for the repair of bone, cartilage, tendons and ligaments.
BioMimetic has received regulatory approvals to market Augment®
Bone Graft in Canada, Australia and New Zealand for use in foot and
ankle fusion indications. Augment is pending regulatory decisions
in the U.S. and European Union for similar indications. The Company
also markets a bone graft substitute line of products for
orthopedic indications called AugmatrixTM Biocomposite Bone
Graft.
For further information, contact Kearstin Patterson, senior
director of corporate communications, at 615-236-4419.
Biomimetic Therapeutics, Inc. (MM) (NASDAQ:BMTI)
過去 株価チャート
から 9 2024 まで 10 2024
Biomimetic Therapeutics, Inc. (MM) (NASDAQ:BMTI)
過去 株価チャート
から 10 2023 まで 10 2024
Real-Time news about Biomimetic Therapeutics, Inc. (MM) (ナスダック市場): 0 recent articles
その他のBioMimetic Therapeutics, Inc.ニュース記事